Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: A model based on registry data

Scandinavian Journal of Rheumatology

Volumn 38, Issue 6, 2009, Pages 409-418

  Kobelt, G ^a,b   Lindgren, P ^c   Geborek, P ^b  

^a European Health Economics SAS   (France)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIMALARIAL AGENT; ETANERCEPT; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL PRACTICE; COMPUTER MODEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISCRETE EVENT SIMULATION MODEL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE REGISTRY; DISEASE SEVERITY; DRUG COST; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; REGISTER; RESOURCE ALLOCATION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SWEDEN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ARTHRITIS, RHEUMATOID; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MODELS, ECONOMIC; REGISTRIES; RETROSPECTIVE STUDIES; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70450164068     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009740902865464     Document Type: Article

References (29)

1. Soderlin MK, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann Rheum Dis 2008;/67:/37-42.
2. Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: Results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008;/47:/ 495-499
3. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006;/54:/2784-92.
4. Jonsson B, Kobelt G, Smolen J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ 2008;/8(Suppl 2):/S61-86.
5. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;/42:/347-56.
6. Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modelling the progression of rheumatoid arthritis: A twocountry model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002;/46:/2310-9.
7. Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. German Collaborative Arthritis Centres. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;/65:/1175-83.
8. Kobelt G, Jonsson B. The burden of rheumatoid arthritis and access to treatment: Outcome and cost-utility of treatments. Eur J Health Econ 2008;/8(Suppl 2):/95-106.
9. Kobelt G, Jonsson L, Young A, Eberhardt K. The costeffectiveness of infliximab [Remicade(R)] in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;/ 42:/326-35.
10. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005;/64:/1174-9.
11. Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;/ 64:/995-1002.
12. Geborek P, Saxne T. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis. Rheumatology (Oxford) 2000;/39:/1159-61.
13. Kobelt G, Eberhardt K, Geborek P. TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: Costs and outcomes in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;/63:/4-10.
14. Karlsson JA, Kristensen LE, Kapetanovic MC, Gulfe A, Saxne T, Geborek P. Treatment response to a second or third TNF-inhibitor in RA: Results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008;/47:/ 507-513
15. The EuroQol Group. EuroQol: A new facility for the measurement of health-related quality of life. Health Policy 1990;16: 199-208.
16. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: Results from a UK general population survey. York: Centre for Health Economics, University of York; 1995.
17. Jacobsson L, Lindroth Y, Marsal L, Tejler L. [The Malmo model for private and public rheumatological outpatient care. Cooperation makes it possible to introduce disease modifying treatment quickly] in Swedish. Lakartidningen 2001;/98:/ 4710-4716
18. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 2005;/44:/1169-75.
19. Jacobsson LT, Lindroth Y, Marsal L, Juran E, Bergstrom U, Kobelt G. Rheumatoid arthritis: What does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden. Scand J Rheumatol 2007;/36:/179-83.
20. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002;/29:/62-7.
21. Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O'Fallon WM, et al. Survival in rheumatoid arthritis: A population-based analysis of trends over 40 years. Arthritis Rheum 2003;/48:/54-8.
22. Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;/66:/670-5.
23. National Statistics Office. 2008. Available from: http://www. scb.se.
24. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000;/39:/122-32.
25. FASS. Lakemedel i Sverige [Pharmaceutical lexicon]. Stockholm: Lakemedelsinformation AB, 2008.
26. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;/66:/1339-44.
27. Kobelt G. Health economic issues in rheumatoid arthritis. Scand J Rheumatol 2006;/35:/415-25.
28. Bansback N, Ara R, Karnon J, Anis A. Economic evaluations in rheumatoid arthritis: A critical review of measures used to define health states. Pharmacoeconomics 2008;/26:/395-408.
29. Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, et al. Modelling the cost effectiveness of TNFalpha antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 2007;/46:/1345-54.